Testagen

Overview

Testagen is a synthetic tetrapeptide — Lys-Glu-Asp-Gly ("KEDG") — from Vladimir Khavinson's family of "short peptide bioregulators," developed in the Russian/CIS tradition associated with the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed toward testicular/testosterone and thyroid "support" with a proposed epigenetic gene-regulation mechanism.

Its chemistry is reasonably well defined by convergent sources: molecular formula C17H29N5O9, average molecular weight 447.44 g/mol (independently recomputed from Lys + Glu + Asp + Gly − 3 H2O), all-L (natural) stereochemistry. The structure H-Lys-Glu-Asp-Gly-OH is independently corroborated by a 2025 Molecules paper — though that study is chemistry (copper-corrosion inhibition), not biology.

The honest evidence picture is thin, older, and mostly Russian. The actual PubMed-indexed primary work is animal — thyroid structure and hormonal activity in neonatally hypophysectomised chickens and old hens (Bull Exp Biol Med 2008 and 2011) — plus in-vitro data that short Khavinson peptides can enter cell nuclei and bind DNA/oligonucleotides (Biochemistry (Moscow) 2011). Vendor "boosts testosterone / testes bioregulator" framing outruns the published biology, which is largely about the thyroid. There are no PubMed-indexed human trials, no pharmacokinetic or toxicology data, and no FDA/EMA approval. It is sold only as a research chemical.

Chemistry and structure

The molecular weight was independently recomputed from the constituent amino acids (Lys + Glu + Asp + Gly − 3 H2O) and agrees with vendor listings and the 2025 Molecules paper. No PubChem compound record could be located for this exact peptide, so the formula/weight rest on independent calculation plus source agreement rather than a PubChem canonical record. The CAS number 1026993-38-3 is vendor-listed only (e.g. BOC Sciences) and does not resolve in PubChem's cross-reference registry — it should be treated as unverified. Monoisotopic mass and canonical SMILES/InChI were not retrieved from a primary chemistry database.

Mechanism of action

• DNA/chromatin interaction and gene-expression modulation — as a short peptide, Testagen is proposed to penetrate the cell and nuclear membranes and interact directly with DNA/chromatin to modulate gene expression (the general Khavinson "peptide bioregulator" epigenetic hypothesis). [In vitro] (Short fluorescently-labeled Khavinson peptides shown to enter HeLa cell nuclei and bind deoxyribo-oligonucleotides/DNA in vitro — Biochemistry (Moscow) 2011, PMID 22117547. Mechanistic only; does not demonstrate a specific clinical effect.)
• Modulation of thyroid structure and hormonal activity — partially corrects hypophysectomy-induced thyroid atrophy, with a greater effect in younger animals. [Animal] (Bull Exp Biol Med 2008 PMID 19024016 and 2011 PMID 22268052; Adv Gerontol 2011 PMID 21809626, Russian; Patol Fiziol Eksp Ter 2010 PMID 20731122, Russian — all in hypophysectomised birds; small, single-group, mostly Russian.)
• Regulation of testicular steroidogenesis / testosterone synthesis — the marketed rationale (the name derives from testis). [Hypothesis] (No PubMed-indexed study demonstrating a testosterone/steroidogenesis effect was found; the verifiable animal biology is thyroid-focused. Treat as vendor hypothesis.)

Research and evidence

Human evidence. No PubMed-indexed human clinical trials were found. Peptide-vendor pages cite a single small controlled report (~36 men with chronic abacterial prostatitis and androgen deficiency, "Testagen" as a testosterone-synthesis inductor, said to be published in a Russian/Ukrainian endocrinology journal), but this citation could not be located or verified in any primary index — no PMID, authors, or year confirmable. Treat human efficacy as unverified/anecdotal [Human]. In short: no well-established human clinical trials. Human dosing, pharmacokinetics (bioavailability, half-life, metabolism, clearance), and toxicology are not established in any verifiable source; vendor "protocols" are not evidence-based.

Status and regulation

Testagen is not approved by the FDA or EMA for any indication, and there is no evidence of a licensed product in any jurisdiction. It is of Russian/CIS origin (developed in the Khavinson tradition at the St. Petersburg Institute of Bioregulation and Gerontology) and is sold only as a research-use-only reagent by peptide vendors. Any human use would make it an unauthorised (unlicensed) medicine — "no specific ban" is not affirmative permission.

WADA status: no source was found addressing whether Testagen is on the WADA Prohibited List, so no class code is stated here. WADA sport-prohibition is a separate axis from legality; do not infer a code from its unapproved status.

Safety

• Human safety profile is not established in verifiable sources — no toxicology, reproductive-toxicity, pharmacokinetic, or drug-interaction data of adequate quality were found.
• The reported biological effects come from animal (bird) and in-vitro models, which do not establish safety in humans.
• Material sold as a research reagent is not a quality-controlled medicine and may vary in identity, purity, and sterility.
• No human dosing has been established; any human use is experimental and unsupervised by design. Vendor dosing charts are not backed by clinical evidence.

Legal status

Testagen's regulatory classification is a research reagent ("research use only") — it is not approved for human use in the US or EU, and no licensed product was identified in any jurisdiction. "No specific ban" is not affirmative permission: a compound becomes an unauthorised medicine the moment it is intended for human use, regardless of how it is labeled at point of sale. Its Russian/CIS origin does not confer legality elsewhere. Regulatory status differs by country and can change. This is not legal advice — verify the status in your own jurisdiction. (Dated 2026-07-08.)

How it compares

• Epitalon — another Khavinson "short peptide bioregulator" and a synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG), sharing Testagen's pattern of bold claims resting on the same research lineage with limited independent replication and no robust human trials.
• Cortagen — a related Khavinson-school tetrapeptide (Ala-Glu-Asp-Pro) marketed for a different organ system (brain/nerve), illustrating the same "one peptide per tissue" bioregulator framing that outruns its published biology.
• Gonadorelin — by contrast, a well-characterised hypothalamic decapeptide (GnRH) with an established endocrine mechanism and approved clinical uses — a useful reference point for how much weaker the Testagen evidence base is on the reproductive/hormonal axis.

Common misconceptions

• "Testagen boosts testosterone — it's proven." No PubMed-indexed study demonstrates a testosterone or steroidogenesis effect. The testes/testosterone framing is a vendor hypothesis [Hypothesis]; the verifiable animal biology is about the thyroid [Animal].
• "There's a human study showing it works." The vendor-cited prostatitis/androgen study (~36 men) could not be verified — no PMID, authors, year, or journal confirmable. Treat human efficacy as unverified [Human].
• "Its CAS number is 1026993-38-3." That is a vendor-listed number that does not resolve in PubChem; there is no PubChem compound record for this exact peptide. Treat the CAS as unverified.
• "It regulates genes by binding DNA in the body." Nuclear penetration and DNA binding are in-vitro observations for short Khavinson peptides [In vitro]; the epigenetic gene-regulation mechanism is a hypothesis, not a demonstrated physiological effect in humans.
• "Not banned means legal to take." No specific ban is not affirmative permission; Testagen is a research reagent and becomes an unauthorised medicine the moment it is intended for human use.

Russian research

Almost all of Testagen's evidence originates from a single Russian lineage — Khavinson's St. Petersburg Institute of Bioregulation and Gerontology and a closely allied Kharkiv urology group — so it is gathered here for completeness and framed honestly for quality rather than presented as independent confirmation.

• The origin story [Hypothesis]. In a self-authored narrative review, Khavinson describes Testagen as the tetrapeptide Lys-Glu-Asp-Gly (KEDG) derived from testis tissue and asserts that it "raises reduced testosterone and normalizes spermatogram indices in animals" (Khavinson V.Kh., Klinicheskaya Meditsina 2020;98(3):165-177, DOI 10.30629/0023-2149-2020-98-3-165-177; open full text on CyberLeninka). Note the important caveat: even in the school's own review, this reproductive claim is asserted without a citation to any primary study — so it is an unreferenced summary statement, not evidence of efficacy.

• The one human clinical citation [Human]. The single small clinical report behind the "testosterone/testes" framing is Rossikhin V.V., Hoshchenko Yu.O. & Osipov P.G., "Efficacy of testosterone synthesis inductor application 'Testagen' in androgenic deficiency in patients with chronic abacterial prostatitis," Problems of Endocrine Pathology (Kharkiv) 2011;36(2):17-22, DOI 10.21856/j-PEP.2011.2.03. Thirty-six men with category IIIA chronic abacterial prostatitis and androgen deficiency received Testagen added on top of standard therapy (alpha-1-adrenolytic plus rectal NSAID suppositories) for about one month; the authors report improved uroflowmetry, reduced prostatic inflammation, and a rise in serum total testosterone. This is the study the article previously flagged as unverifiable: it is now traceable to a real citation, but it remains a single-group, ~36-patient, open (non-blinded, adjunctive) report with no placebo arm for the peptide in isolation and no long-term follow-up, never independently replicated (0 citations in the Ukrainian OUCI index). Being cited is not the same as being proven — the evidence level should not rise on the strength of it.

• A developer-authored register description [Human]/[Animal]. A Russian drug-register monograph — Khavinson V.Kh. & Ryzhak G.A., "Clinical and experimental study of the peptide bioregulator Testagen," on the RLS-Net register (rlsnet.ru) — describes rat organ-culture tissue-specificity tests, a male-rat whole-body-irradiation accelerated-aging model, and a clinical study of 48 men aged 54-68 with male climacteric syndrome (27 treated vs 21 control, 20-day course), reporting improved sperm parameters and hormone normalization. This has a verifiable URL but is a manufacturer-aligned, developer-authored register monograph with no PMID or DOI and no peer review; the 48-man figures should be read as register-reported, not independently verified, and not as efficacy proof.

• The one mechanistic detail that checks out [In vitro]. The only sequence-level mechanism actually published for Testagen is that KEDG preferentially binds CAG-containing DNA sequences in cell and binding assays (Fedoreyeva L.I., Kireev I.I., Khavinson V.Kh. & Vanyushin B.F., Biochemistry (Moscow) 2011, PMID 22117547). This is in-vitro only and is not evidence of any testicular or endocrine effect in a living organism.

• What could NOT be verified. Vendor and AI-generated pages describe a rat study (attributed to "Advances in Gerontology, 2010") in which aged males given Testagen improved Leydig-cell testosterone output and sperm morphology with StAR gene upregulation, "regained the ability to sire offspring," and in which the peptide "interacts with the hypothalamic-pituitary-gonadal axis to stimulate Leydig cell activity." Russian-language sources describe these reproductive claims, but no independently verifiable citation was found — no PMID, DOI, or CyberLeninka/eLIBRARY record, and PubMed indexes zero KEDG testis/Leydig/spermatogenesis studies. Treat this as unverified, likely confabulated vendor content; it must not be cited. Likewise, the vendor-listed CAS number 1026993-38-3 does not resolve in PubChem, and no WADA Prohibited List status could be located.

Quality note. The evidence remains thin, old, single-institute, and essentially unreplicated: human data amount to one small unblinded adjunctive prostatitis report (~36 men) plus a developer-authored register description (48 men), the only PubMed-indexed KEDG biology is thyroid-in-birds and in-vitro DNA binding, and no independent non-Russian/CIS replication exists. Separately, Testagen is sold in Russia/CIS as a peptide dietary supplement (БАД) — not a registered medicine — while in the US/EU it is offered only as a research-use-only reagent with no FDA/EMA approval; a Russian supplement (БАД) registration is a regulatory and marketing fact that requires no controlled efficacy trials and is not proof that the compound works.